The evolution of clinical trials for infant acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 4, Issue 4, 2014, Pages

  Kotecha, R S ^a,b,c   Gottardo, N G ^a,b,c   Kees, U R ^b   Cole, C H ^a,b,c  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LESTAURTINIB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PLERIXAFOR; PREDNISOLONE; PREDNISONE; RG 7112; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE; ZEBULARINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; DONOR SELECTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXPERIMENTAL THERAPY; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK INFANT; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SYSTEMIC THERAPY; WHOLE BODY RADIATION;

EID: 84901950504     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.17     Document Type: Review

References (111)

1. Linabery AM, Ross JA. Trends in childhood cancer incidence in the US (1992-2004). Cancer 2008; 112: 416-432.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF et al. (eds) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute: Bethesda, MD, 2013. http://seer.cancer.gov/csr/1975-2010/based on November 2012 SEER data submission, posted to the SEER web site.
3. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238: 787-793.
4. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 1663-1669.
5. O'Leary M, Krailo M, Anderson JR, Reaman GH. ProgRes.s in childhood cancer: 50 years of Res.earch collaboration, a report from the Children's Oncology Group. Semin Oncol 2008; 35: 484-493.
6. Modan B, Virag I, Modan M. Survival in childhood malignancies: assessment of the influence of age, sex, and tumor type, with emphasis on 'long-term survivors'. J Natl Cancer Inst 1969; 43: 349-363.
7. Zippin C, Cutler SJ, Reeves Jr. WJ, Lum D. Variation in survival among patients with acute lymphocytic leukemia. Blood 1971; 37: 59-72.
8. George SL, Fernbach DJ, Vietti TJ, Sullivan MP, Lane DM, Haggard ME et al. Factors influencing survival in pediatric acute leukemia. The SWCCSG experience, 1958-1970. Cancer 1973; 32: 1542-1553.
9. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-915.
10. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ et al. Intensified therapy for infants with acute lymphoblastic leukemia: Res.ults from the Dana-Farber Cancer Institute Consortium. Cancer 1997; 80: 2285-2295.
11. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S et al. Prednisone Res.ponse is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
12. Reaman G, Zeltzer P, Bleyer WA, Amendola B, Level C, Sather H et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985; 3: 1513-1521.
13. Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finklestein JZ, Evans R et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 1987; 71: 1033-1038.
14. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445-455.
15. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN et al. Long-term Res.ults of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia 2010; 24: 285-297.
16. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108: 441-451.
17. Kaleita TA, Reaman GH, MacLean WE, Sather HN, Whitt JK. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report. Cancer 1999; 85: 1859-1865.
18. Salzer W, Dinndorf P, Dreyer Z, Hilden J, Reaman GH. Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 2009; 31: 398-405.
19. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP et al. Long-term Res.ults of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia 2010; 24: 355-370.
20. Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997; 19: 35-42.
21. Lauer SJ, Camitta BM, Leventhal BG, Mahoney Jr. D, Shuster JJ, Kiefer G et al. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: a Pediatric Oncology Group pilot study. J Pediatr Hematol Oncol 1998; 20: 229-233.
22. Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S et al. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatr Blood Cancer 2012; 59: 834-839.
23. Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. J Clin Oncol 2011; 29: 214-222.
24. Brown P, Hilden JM, Dreyer ZE, Winick NJ, Salzer W, Raetz E et al. Report on excessive induction toxicity in infants with ALL enrolled on COG protocol AALL0631: a Children's Oncology Group study. Blood 2009; 114: 3091.
25. Salzer W, Jones T, Dreyer Z, Gore L, Winick N, Sung L et al. Decreased induction morbidity and mortality with changes to induction therapy in infants with acute lymphoblastic leuekemia enrolled on Children's Oncology Group (COG) trial AALL0631. Pediatr Blood Cancer 2012; 58: 409.
26. Brown P, Kaeding A, Magoon D, Small D, Jones T, Devidas M et al. Identification of a safe and biologically active dose of the FLT3 inhibitor lestaurtinib in combination with chemotherapy in infants with MLL-rearranged (MLL-R) ALL: a Children's Oncology Group study. Pediatr Blood Cancer 2011; 56: 302B.
27. Sun D, Kaeding A, Magoon D, Jones T, Devidas M, Carroll AJ et al. Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631. J Clin Oncol 2012; 30(15-Suppl): 9548.
28. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106: 2484-2490.
29. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004; 103: 1085-1088.
30. Stam RW, den Boer ML, Schneider P, Meier M, Beverloo HB, Pieters R. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica 2007; 92: 1565-1568.
31. Emerenciano M, Menezes J, Vasquez ML, Zalcberg I, Thuler LC, Pombo-de-Oliveira MS. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. Leuk Lymphoma 2008; 49: 2291-2297.
32. Chen CS, Sorensen PH, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
33. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994; 84: 570-573.
34. Taki T, Ida K, Bessho F, Hanada R, Kikuchi A, Yamamoto K et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996; 10: 1303-1307.
35. Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: Res.ults of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 2002; 118: 999-1010.
36. Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104: 3527-3534.
37. Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007; 21: 2258-2263.
38. Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: Res.ults from the Japan Infant Leukemia Study Group. Blood 2006; 107: 4663-4665.
39. Tomizawa D, Koh K, Hirayama M, Miyamura T, Hatanaka M, Saikawa Y et al. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: a report from the Japan Infant Leukemia Study Group. Pediatr Blood Cancer 2009; 52: 808-813.
40. Koh K, Tomizawa D, Saito AM, Watanabe T, Ogawa A, Sato T et al. Early phase administration of hematopoietic stem cell transplantation to prevent early relapse for infants with acute lymphoblastic leukemia and MLL gene rearrangement; a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) trial MLL03. Blood 2010; 116: 529.
41. Miyamura T, Koh K, Tomizawa D, Sato T, Kato K, Sugita K et al. Nation-wide survey of relapsed infantile acute lymphoblastic leukemia in Japan: treatment and outcome from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) MLL03 study. Blood 2010; 116: 1025.
42. Chessells JM, Eden OB, Bailey CC, Lilleyman JS, Richards SM. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Res.earch Council Working Party on Childhood Leukaemia. Leukemia 1994; 8: 1275-1279.
43. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: Res.ults of the UK Infant Protocols 1987-1999. Br J Haematol 2002; 117: 306-314.
44. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250.
45. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: Res.ults from the Interfant-99 Study. Blood 2010; 116: 2644-2650.
46. van der Linden MH, Valsecchi MG, De Lorenzo P, Moricke A, Janka G, Leblanc TM et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood 2009; 114: 3764-3768.
47. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G et al. Prognostic significance of minimal Res.idual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079.
48. Marco F, Bureo E, Ortega JJ, Badell I, Verdaguer A, Martinez A et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Espanol de Trasplante de Medula Osea en Ninos. J Clin Oncol 2000; 18: 3256-3261.
49. Jacobsohn DA, HewLett. B, Morgan E, Tse W, Duerst RE, Kletzel M. Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 999-1005.
50. Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005; 105: 3749-3756.
51. Corker E, Astwood E, Williams J, Vora A. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia. Br J Haematol 2012; 159: 104-106.
52. Bordigoni P, Benz-Lemoine E, Vannier JP, Fischer A. Bone marrow transplantation following busulfan, cyclophosphamide and high dose cytosine-arabinoside as treatment for infants with translocation (4;11) acute leukaemia. Br J Haematol 1989; 72: 293-294.
53. von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, Demeocq F, Mechinaud-Lacroix F, Michel G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1995; 16: 521-527.
54. Ayas M, Belgaumi A, Al-Mahr M, Al-Jefri A, Solh H, Leung W. Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen? Bone Marrow Transplant 2002; 29: 630; author reply 631.
55. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
56. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa 3rd R, Patel Y, Harden A et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 1991; 88: 10735-10739.
57. Cimino G, Moir DT, Canaani O, Williams K, Crist WM, Katzav S et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res. 1991; 51: 6712-6714.
58. Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG et al. Frequencies and prognostic impact of RAS mutations in MLLrearranged acute lymphoblastic leukemia in infants. Haematologica 2013; 98: 937-944.
59. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Kinukawa N, Ishii E et al. mRNA expRes.sion of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expRes.sion is an independent predictor for poor prognosis. Leukemia 2004; 18: 365-368.
60. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expRes.sion profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835-2844.
61. Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR et al. Gene expRes.sion profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012; 119: 1872-1881.
62. Stumpel DJ, Schneider P, van Roon EH, Pieters R, Stam RW. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemiarearranged infant acute lymphoblastic leukaemia. Eur J Cancer 2013; 49: 175-184.
63. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009; 114: 5490-5498.
64. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 2010; 115: 4798-4809.
65. Stumpel DJ, Schotte D, Lange-Turenhout EA, Schneider P, Seslija L, de Menezes RX et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 2011; 25: 429-439.
66. Nishi M, Eguchi-Ishimae M, Wu Z, Gao W, Iwabuki H, Kawakami S et al. SuppRes.sion of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements. Leukemia 2013; 27: 389-397.
67. Stumpel DJ, Schneider P, Seslija L, Osaki H, Williams O, Pieters R et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 2012; 26: 682-692.
68. Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly AD et al. Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol 2008; 141: 827-839.
69. Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG et al. Association of high-level MCL-1 expRes.sion with in vitro and in vivo prednisone Res.istance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010; 115: 1018-1025.
70. Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS et al. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 2013; 121: 2689-2703.
71. Jayanthan A, Incoronato A, Singh A, Blackmore C, Bernoux D, Lewis V et al. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatr Blood Cancer 2011; 56: 353-360.
72. Qazi S, Uckun FM. Gene expRes.sion profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Br J Haematol 2010; 149: 865-873.
73. Urtishak KA, Wang LS, Teachey DT, Sarah TK, Barrett JS, Chen IM et al. PIK3/AKT/mTOR signaling is a significant druggable pathway in infant acute lymphoblastic leukemia (ALL). Blood 2013; 122: 1669.
74. Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clinical Cancer Res. 2013; 19: 1795-1805.
75. Lock RB, Richmond J, High L, Hernan C, Evans K, Mendomo AM et al. Effective targeting of the P53/MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Blood 2013; 122: 71.
76. Spijkers-Hagelstein JA, Schneider P, Hulleman E, de Boer J, Williams O, Pieters R et al. Elevated S100A8/S100A9 expRes.sion causes glucocorticoid Res.istance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2012; 26: 1255-1265.
77. Spijkers-Hagelstein JA, Mimoso Pinhancos S, Schneider P, Pieters R, Stam RW. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid Res.istance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2013; 27: 1063-1071.
78. Spijkers-Hagelstein JAP, Pinhanços SS, Schneider P, Pieters R, Stam RW. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid Res.istance in MLL-rearranged infant ALL. Leukemia 2013; e-pub ahead of print 20 August 2013; doi:10.1038/leu.2013.245.
79. Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic Res.istance that can be overcome with CXCR4 antagonism. Br J Haematol 2013; 160: 785-797.
80. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53-65.
81. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122: 1017-1025.
82. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012; 8: 277-284.
83. Accordi B, Galla L, Milani G, Curtarello M, Serafin V, Lissandron V et al. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia 2013; 27: 1019-1027.
84. Sung NS, Crowley Jr WF, Genel M, Salber P, Sandy L, Sherwood LM et al. Central challenges facing the national clinical Res.earch enterprise. JAMA 2003; 289: 1278-1287.
85. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366: 1371-1381.
86. Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT et al. Late effects in survivors of infant leukemia. Leukemia 2000; 14: 1185-1190.
87. Felix CA. Infant leukemia 2010: a call to action for the west and the 'four Asian Tigers'. Pediatr Blood Cancer 2010; 55: 1247-1249.
88. Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C et al. Long-term Res.ults of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 255-264.
89. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Long-term Res.ults of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
90. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term Res.ults of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14: 2257-2266.
91. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239.
92. Jabali Y, Stary J, Hak J, Blazek B, Hrstkova H, Mihal V et al. Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic. Med Pediatr Oncol 2000; 35: 493-495.
93. Stary J, Jabali Y, Trka J, Hrusak O, Gajdos P, Hrstkova H et al. Long-term Res.ults of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 2010; 24: 425-428.
94. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term Res.ults of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010; 24: 309-319.
95. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L et al. Long-term Res.ults of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 320-334.
96. Donadieu J, Auclerc MF, Baruchel A, Leblanc T, Landman-Parker J, Perel Y et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group. Br J Haematol 1998; 102: 729-739.
97. Oudot C, Auclerc MF, Levy V, Porcher R, Piguet C, Perel Y et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26: 1496-1503.
98. Stark B, Nirel R, Avrahami G, Abramov A, Attias D, Ballin A et al. Long-term Res.ults of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 2010; 24: 419-424.
99. Horibe K, Hara J, Yagi K, Tawa A, Komada Y, Oda M et al. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study. Int J Hematol 2000; 72: 61-68.
100. Tsurusawa M, Shimomura Y, Asami K, Kikuta A, Watanabe A, Horikoshi Y et al. Long-term Res.ults of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 335-344.
101. Matsuzaki A, Ishii E, Okamura J, Eguchi H, Yoshida N, Yanai F et al. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Med Pediatr Oncol 1996; 26: 10-19.
102. Yeoh AE, Ariffin H, Chai EL, Kwok CS, Chan YH, Ponnudurai K et al. Minimal Res.idual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Res.ults from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 2012; 30: 2384-2392.
103. Gustafsson G, Schmiegelow K, FoRes.tier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267-2275.
104. Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Perez-Hurtado JM et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 2007; 25: 16-24.
105. Campbell M, Salgado C, Quintana J, Becker A, Vargas L, Cabrera ME et al. Improved outcome for acute lymphoblastic leukemia in children of a developing country: Res.ults of the Chilean National Trial PINDA 87. Med Pediatr Oncol 1999; 33: 88-94.
106. Pui CH, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP et al. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term Res.ults of St Jude total therapy study X. Leukemia 1992; 6: 150-157.
107. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term Res.ults of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 371-382.
108. Tsuchida M, Ikuta K, Hanada R, Saito T, Isoyama K, Sugita K et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia 2000; 14: 2295-2306.
109. Liang DC, Yang CP, Lin DT, Hung IJ, Lin KH, Chen JS et al. Long-term Res.ults of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 397-405.
110. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical Res.earch council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 2010; 24: 406-418.
111. Biondi A, Rizzari C, Valsecchi MG, De Lorenzo P, Arico M, Basso G et al. Role of treatment intensification in infants with acute lymphoblastic leukemia: Res.ults of two consecutive AIEOP studies. Haematologica 2006; 91: 534-537.